Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
58.41
-0.52 (-0.88%)
At close: Sep 18, 2026, 4:00 PM EDT
58.47
+0.06 (0.10%)
After-hours: Sep 18, 2026, 7:57 PM EDT
Royalty Pharma Revenue
Royalty Pharma had revenue of $674.14M in the quarter ending June 30, 2026, with 16.50% growth. This brings the company's revenue in the last twelve months to $2.54B, up 10.01% year-over-year. In the year 2025, Royalty Pharma had annual revenue of $2.38B with 5.06% growth.
Revenue (ttm)
$2.54B
Revenue Growth
+10.01%
P/S Ratio
13.24
Revenue / Employee
$25,359,980
Employees
100
Market Cap
33.59B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.38B | 114.62M | 5.06% |
| Dec 31, 2024 | 2.26B | -90.98M | -3.86% |
| Dec 31, 2023 | 2.35B | 117.34M | 5.24% |
| Dec 31, 2022 | 2.24B | -52.25M | -2.28% |
| Dec 31, 2021 | 2.29B | 167.11M | 7.87% |
| Dec 31, 2020 | 2.12B | 308.10M | 16.98% |
| Dec 31, 2019 | 1.81B | 19.36M | 1.08% |
| Dec 31, 2018 | 1.79B | 196.96M | 12.33% |
| Dec 31, 2017 | 1.60B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| argenx SE | 5.32B |
| Alnylam Pharmaceuticals | 4.80B |
| Jazz Pharmaceuticals | 4.60B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Moderna | 2.23B |
RPRX News
- 4 days ago - Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program - GlobeNewsWire
- 5 days ago - Royalty Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 10 days ago - Royalty Pharma to present at upcoming investor conferences - GlobeNewsWire
- 15 days ago - Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen - GlobeNewsWire
- 4 weeks ago - Zealand Pharma enters $100M royalty purchase, sale pact with Royalty Pharma - TheFly
- 5 weeks ago - Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million - GlobeNewsWire
- 5 weeks ago - Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide - GlobeNewsWire
- 5 weeks ago - Royalty Pharma Slides: Corporate presentation - Filings